- Establishes ‘AI-driven Organ Lifecycle Management Model’ integrating AI-driven organ aging prediction, management, and regeneration
- Organ reverse-aging solutions, including NMN, listed on national flagship airline duty-free channels in November
- Accelerates global launch across the U.S. and Asia

ROKIT Healthcare (CEO Seokhwan You), an AI-driven hyper-personalized organ regeneration platform company, is launching its full-scale "AI-driven Reverse-Aging Platform" strategy centered on NMN (Nicotinamide Mononucleotide). The company envisions building an "Organ Lifecycle Management Model" that goes beyond simple NMN sales by connecting organ aging prediction/analysis, organ regeneration therapy, and daily health management into a single cohesive system.

ROKIT America, a subsidiary of ROKIT Healthcare, has entered the global market with a premium reverse-aging product developed by combining high-purity NMN (99.9%) with Pterostilbene, which boasts a high absorption rate. This solution is designed with medical evidence, applying data and know-how accumulated through organ regeneration clinical trials (cartilage, skin, kidney) to its reverse-aging formula. The company has already secured safety data through trials conducted at GLP facilities and plans to diversify into safer and more effective formulas based on this data.

The global distribution strategy is also intrinsically linked to the data platform. In November, NMN products were officially listed in a national flagship airline’s catalog, marking the beginning of a full-scale launch in the U.S. and Asia. The goal is to realize an "AI-driven Organ Management Platform" that manages daily organ aging over the long term. This involves predicting individual aging patterns and organ-specific risks using genomic and single-cell analysis, forecasting organ damage/recovery curves based on regeneration clinical data, and providing NMN-based nutritional formulas alongside lifestyle coaching. A company official stated, "We are building a reverse-aging infrastructure that manages AI-driven organ prediction analysis, organ regeneration, and NMN-based nutritional solutions on a single platform." They added, "Through the integration of our NMN formula pipeline, distribution channels, and data, we aim to leap forward as a global AI organ regeneration and reverse-aging platform company that provides an organ management experience of '10 years younger, 10 years healthier'."